Dr. Jung Min Lee, M.D.

Jung-Min Lee, M.D.

  • Center for Cancer Research
  • National Cancer Institute
Women's Malignancies Branch


Dr. Lee’s research focuses on developing targeted therapies for ovarian carcinoma. Her studies have identified key proteins of DNA damage response pathways as therapeutic targets, opening up possibilities for novel therapies for this disease. Her research also emphasizes the collection of patient samples to better understand treatment response and tumor biology. Dr. Lee is the Principal Investigator of multiple investigator-initiated clinical trials and the Study Chair of multi-center Phase II/III clinical trials.

Areas of Expertise

BRCA Mutation
Triple Negative Breast Cancer
Early Clinical Trials

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them. 


Selected Key Publications

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study

Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee MJ, Bagheri MH, Botesteanu DA, Steinberg SM, Minasian L, Ekwede I, and Kohn EC.
Lancet Oncol. 19(2): 207-215, 2018. [ Journal Article ]

Targeting the PI3K/mTOR pathway augments CHK1 inhibitor-induced replication stress and antitumor activity in high-grade serous ovarian cancer

Huang TT, Brill E, Nair JR, Zhang X, Wilson KM, Chen L, Thomas CJ, Lee JM
Cancer Research. 80(23): 5380-5392, 2020. [ Journal Article ]

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor-resistant BRCA-mutant ovarian cancer

Gupta N, Huang TT, Nair JR, An D, Zurcher G, Lampert EJ, McCoy A, Cimino-Mathres A, Swisher EM, Radke MR, Lockwood CM, Reichel JB, Chiang CY, Wilson KM, Cheng KC, Nousome D, Lee JM
Science Translational Medicine. 15/701: 2023.
Full-Text Article
[ Journal Article ]

Safety and Clinical Activity of the PD-L1 Inhibitor Durvalumab in Combination With a PARP Inhibitor, Olaparib, or a VEGFR1-3 Inhibitor, Cediranib, in Women's Cancers: A Dose-Escalation, Phase I Study

Lee J, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, Cao L, Harrell M, Swisher E, Houston N, Botesteanu DA, Taube JM, Thompson E, Ogurtsova A, Xu H, Nguyen J, Ho TW, Figg WD, and Kohn EC.
J Clin Oncol. 35(19): 2193-2202, 2017. [ Journal Article ]

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-or-Concept Phase II Study

Lampert EJ, Zimmer A, Padget M, Cimino-Mathews A, Nair JR, Liu Y, Swisher EM, Hodge JW, Nixon AB, Nichols E, Bagheri MH, Levy E, Radke MR, Lipkowitz S, Annunziata CM, Taube JM, Steinberg SM, Lee JM
Clinical Cancer Research. 26(16): 4268-4279, 2020. [ Journal Article ]

Job Vacancies

We have no open positions in our group at this time, please check back later.

To see all available positions at CCR, take a look at our Careers page. You can also subscribe to receive CCR's latest job and training opportunities in your inbox.


Research Fellow
Tzu-Ting Huang, Ph.D.
Jayakumar Nair, Ph.D.
Investigator Trainee
Chi-Ting Shih, Ph.D.
Nurse Practitioner
Britanny Brooke Solarz , R.N., B.S.N.
Research Nurse
Ann McCoy, R.N.